

**SEPTEMBER 2022 PROFILE DATA SUMMARY**

SUBMITTED	PROFILE	% PROFILE
2017	3	2%
2018	11	8%
2019	29	22%
<b>2020</b>	<b>54</b>	<b>41%</b>
2021	23	18%
2022	11	8%
DATE UNAVAIL.	109	45%
TOTAL	240	

YEAR OF DIAGNOSIS	PROFILE	% REPORTED
2008	1	1%
2009	1	1%
2010	1	1%
2011	4	2%
2012	11	6%
2013	8	4%
2014	5	3%
2015	13	7%
2016	15	8%
2017	18	10%
2018	24	13%
<b>2019</b>	<b>33</b>	<b>18%</b>
2020	23	13%
2021	20	11%
2022	6	3%
TOTAL	183	

GENDER	PROFILE	% REPORTED
<b>FEMALE</b>	<b>218</b>	<b>99.5%</b>
TRANSGENDER	1	0.4%
NOT REPORTED	21	9%
TOTAL	240	

RACE	PROFILE	% REPORTED
BLACK	3	1.5%
MULTIRACIAL	1	0.5%
<b>WHITE</b>	<b>196</b>	<b>98.0%</b>
NOT REPORTED	40	17%
TOTAL	240	

ETHNICITY	PROFILE	% REPORTED
HISPANIC	13	13%
<b>NON-HISPANIC</b>	<b>86</b>	<b>87%</b>
NOT REPORTED	141	59%
TOTAL	240	

ADM USE	PROFILE	% REPORTED
<b>NO</b>	<b>152</b>	<b>87%</b>
YES	22	13%
TOTAL	174	

FAT GRAFTING	PROFILE	% REPORTED
<b>NO</b>	<b>190</b>	<b>94%</b>
YES	12	6%
TOTAL	202	

TIME HAVING CURRENT IMPLANTS	(YEARS)
RANGE (LOW)	0.08
RANGE (HIGH)	40.09
<b>AVERAGE</b>	<b>10.63</b>
<b>MEDIAN</b>	<b>9.57</b>

IMPLANT FILL	PROFILE	% REPORTED
SALINE	115	39.2%
SALINE/SILICONE	6	2.0%
<b>SILICONE</b>	<b>178</b>	<b>60.8%</b>
POLYURETHANE FOAM	2	0.7%
MULTIPLE	8	EXCLUDED TOTAL
NOT REPORTED	4	1.3%
TOTAL	305	

IMPLANT TEXTURE	PROFILE	% REPORTED
<b>TEXTURED (INC W/HX OF SMOOTH)</b>	<b>403</b>	<b>97.8%</b>
SMOOTH*	7	1.7%
POLYURETHANE	2	0.5%
NOT REPORTED	3	0.7%
TOTAL	415	

\*confirmed 3 previous textured implants, 1 TEXT expander; 3 to do chart review

INDICATION	PROFILE	%REPORTED
<b>AUGMENTATION</b>	<b>91</b>	<b>57.2%</b>
RECONSTRUCTION	68	42.8%
NOT REPORTED	81	33.8%
TOTAL	240	

SYSTEMIC SYMPTOMS	PROFILE	%REPORTED
<b>NO</b>	<b>198</b>	<b>90.0%</b>
YES	22	10.0%
TOTAL	220	

SYSTEMIC SYMPTOMS	PROFILE	%REPORTED
NON-BREAST SKIN LESIONS	2	0.8%
FEVERS	9	3.8%
<b>NIGHT SWEATS</b>	<b>10</b>	<b>4.2%</b>
WEIGHT LOSS	6	2.5%
ONLY REPORTED SYMPTOM		
<b>NON-BREAST SKIN LESIONS</b>	<b>1</b>	<b>0.4%</b>
FEVERS	0	0%
NIGHT SWEATS	0	0%
WEIGHT LOSS	0	0%

LOCAL SYMPTOMS	PROFILE	%REPORTED
NO	13	5.7%
<b>YES</b>	<b>215</b>	<b>94.3%</b>
TOTAL	228	

LOCAL SYMPTOMS	PROFILE	%REPORTED
BREAST SKIN LESIONS	17	7.1%
PAIN	91	37.9%
REDNESS	27	11.3%
<b>SEROMA</b>	<b>179</b>	<b>74.6%</b>
AXILLARY LYMPHADENOPATHY	16	6.7%
BREAST MASS	37	15.4%
CAPSULAR CONTRACTURE	67	27.9%
ONLY REPORTED SYMPTOM		
BREAST SKIN LESIONS ONLY	1	0.4%
PAIN ONLY	1	0.4%
REDNESS ONLY	0	0.0%
SEROMA ONLY	14	5.8%
AXILLARY LYMPHADENOPATHY ONLY	1	0%
BREAST MASS ONLY	2	0.8%
CAPSULAR CONTRACTURE ONLY	6	2.5%

**BIA-ALCL GLOBAL NETWORK CASE COUNTS (as of September 2022)**

Country	Cases	Deaths	Country	Cases	Deaths
Argentina	17	0	Malaysia	1	0
Australia	112	4	Mexico	14	0
Austria	6	0	Netherlands	70	2
Belgium (inc. Luxembourg)	26	0	New Zealand	20	1
Brazil	31	1	Norway	13	0
Bulgaria	1	0	Panama	1	0
Canada	38	1	Poland	10	0
Chile	2	0	Portugal	1	0
China	1	0	Romania	2	0
Colombia	17	1	Russia	8	0
Croatia	1	0	Singapore	1	0
Czech Republic	1	1	Slovenia	1	0
Denmark	13	0	South Africa	5	0
Egypt	1	0	South Korea	3	0
Finland	17	0	Spain	74	3
France	99	4	Sweden	8	2
Germany	30	0	Switzerland	11	0
Greece	1	0	Taiwan	1	0
Hungary	1	0	Thailand	1	0
Ireland	1	0	Turkey	4	0
Israel	9	0	United Kingdom	78	1
Italy	73	2	United States	402	8
Japan	4	0	Venezuela	2	0
<b>TOTAL CASES</b>			<b>1233</b>		
<b>TOTAL DEATHS</b>			<b>31</b>		